| # |
Company Name
|
Industry Name
|
Latest Price (Rs.)
|
Price Change
Rs (%) |
Market Cap
|
Net Sales
(Rs. Cr.) |
Latest EPS
(Rs.) |
Net Profit
Margin % |
Latest
P/E |
Latest
P/BV |
|---|---|---|---|---|---|---|---|---|---|---|
| Dr. Reddys Lab | Pharmaceuticals& Drugs | 1,323 |
-7.15 (-0.54%) |
Mid Cap | 32,644 | 66.7 | 16.93 | 19.9 | 3 | |
| Zydus Lifesciences | Pharmaceuticals& Drugs | 891.7 |
-18.75 (-2.06%) |
Mid Cap | 23,242 | 49.1 | 19.92 | 18.6 | 3.5 | |
| Lupin | Pharmaceuticals& Drugs | 2,303.7 |
-7.2 (-0.31%) |
Mid Cap | 22,708 | 101.6 | 14.55 | 22.7 | 5.1 | |
| Glenmark Pharma | Pharmaceuticals& Drugs | 2,405.6 |
-5.05 (-0.21%) |
Mid Cap | 13,322 | 37.7 | 9.67 | 63.9 | 6.8 | |
| Aurobindo Pharma | Pharmaceuticals& Drugs | 1,389.6 |
-6.95 (-0.5%) |
Mid Cap | 10,933 | 36.7 | 15.17 | 38.1 | 3.7 | |
| Mankind Pharma | Pharmaceuticals& Drugs | 2,246.6 |
-8.05 (-0.36%) |
Mid Cap | 9,498 | 41.3 | 18.61 | 54.6 | 5.8 | |
| Alkem Laboratories | Pharmaceuticals& Drugs | 5,404.1 |
61.1 (1.14%) |
Mid Cap | 8,813 | 183.5 | 23.18 | 29.1 | 4.5 | |
| Ipca Laboratories | Pharmaceuticals& Drugs | 1,531.2 |
-10.55 (-0.68%) |
Mid Cap | 6,635 | 31.7 | 12.45 | 48.6 | 5.1 | |
| Abbott India | Pharmaceuticals& Drugs | 25,430.9 |
-53.65 (-0.21%) |
Mid Cap | 6,409 | 717.3 | 22.1 | 35.5 | 12.3 | |
| Laurus Labs | Pharmaceuticals& Drugs | 1,099.1 |
-6.6 (-0.6%) |
Mid Cap | 5,554 | 15.6 | 5.63 | 70.8 | 11.8 | |
| Glaxosmithkline Phar | Pharmaceuticals& Drugs | 2,335.6 |
-35.4 (-1.49%) |
Mid Cap | 3,749 | 60.3 | 23.42 | 39.3 | 20.1 | |
| Biocon | Pharmaceuticals& Drugs | 359.6 |
-2.75 (-0.76%) |
Mid Cap | 2,243 | 0.1 | 8.04 | 7,935.9 | 2.2 | |
| Anthem Biosciences | Pharmaceuticals& Drugs | 759.8 |
-15.95 (-2.06%) |
Mid Cap | 1,841 | 9 | 27.24 | 86.1 | 14.7 |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: